阿伐他汀对糖尿病肾病患者血清内皮素 心钠素水平的研究

目的比较糖尿病肾病（DN）患者阿伐他汀治疗前后心钠素（ANP）、内皮素（ET-1）含量的变化。并探讨其临床意义。方法40例糖尿病肾病患者随机分为阿伐他汀治疗组和常规组，分别于治疗前和治疗半年后抽血检测血浆ET-1和ANP浓度的变化。ET-1、ANP的检测用放射免疫法。结果阿伐他汀治疗组血浆ET-1、ANP水平与治疗前相比显著降低（P〈0．01），且与常规组相比，差异有统计学意义（P〈0．01）。结论阿伐他汀能够降低ET-1，ANP水平，改善糖尿病肾病血管内皮功能。

Objective To investigate changes in serum level of atrial natrinretic peptides （ ANP）, endothelin - 1 （ ET - 1 ）, before and after atorvastatin treatment in patients with diabetic nephropathy（DN）. Methods The serum level of ANP and ET - 1 were measured in 20 DN cases and 20 routine treatment cases using radioimmunoassary. Results The serum levels of ET - 1 and ANP significantly increased in the patients with DN compared with those in the normal controls （P 〈 0. 01 ）. The serum levels of ET - 1 and ANP after treatment were significantly lower than those before therapy. The serum levels of ET - 1 and ANP in treatment group were lower than those in routine group after treatment for 6 months （ P 〈 0.01 ）. Conclusions Atorvastatin reduces the serum levels of ET - 1 and ANP and improves the function of vascular endothelium in diabetic nephropathy.